A gyulladásos bélbetegségek gyógyszeres kezelése: Crohn-betegség

Translated title of the contribution: Medical therapy of inflammatory bowel diseases: Crohn's disease

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The therapy of inflammatory bowel diseases is based on 5-aminosalicylates (5-ASAs) that are the forefront of treatment of mild-to-moderate active disease and maintenance; steroids are used for the treatment of moderate-to-severe active disease; immunosuppressives and sometimes antibiotics in moderate-to-severe disease; maintenance and for the treatment of selected complications. The last few years have witnessed a significant change in the treatment of Crohn's disease. Based on evidence from new clinical studies and recent meta-analyses, the role of and indications for conventional therapy have been reassessed. The 5-ASAs are nowadays less frequently used in both active disease and maintenance therapy. Instead, budesonide has been introduced in the treatment of mild-to-moderate ileal disease. Besides the modest use of 5-ASAs, steroids are prescribed for active colonic disease. Immunosuppressives, especially azathioprine, are more commonly used in moderate-to-severe disease as well as in maintenance. The preferred maintenance regimen following medically- and surgically-induced remission, in addition to relationship between medical and surgical therapies, has also changed. The recent introduction of new "biological" therapy represents a major, promising change in the therapy of resistant and penetrating disease.

Original languageHungarian
Pages (from-to)1107-1114
Number of pages8
JournalOrvosi Hetilap
Volume148
Issue number24
DOIs
Publication statusPublished - Jun 17 2007

Fingerprint

Inflammatory Bowel Diseases
Crohn Disease
Mesalamine
Maintenance
Therapeutics
Immunosuppressive Agents
Ileal Diseases
Steroids
Colonic Diseases
Budesonide
Biological Therapy
Azathioprine
Meta-Analysis
Anti-Bacterial Agents

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A gyulladásos bélbetegségek gyógyszeres kezelése : Crohn-betegség. / Lakatos, L.; Lakatos, P.

In: Orvosi Hetilap, Vol. 148, No. 24, 17.06.2007, p. 1107-1114.

Research output: Contribution to journalArticle

@article{a6eeaab681234a119b42438cdced211f,
title = "A gyullad{\'a}sos b{\'e}lbetegs{\'e}gek gy{\'o}gyszeres kezel{\'e}se: Crohn-betegs{\'e}g",
abstract = "The therapy of inflammatory bowel diseases is based on 5-aminosalicylates (5-ASAs) that are the forefront of treatment of mild-to-moderate active disease and maintenance; steroids are used for the treatment of moderate-to-severe active disease; immunosuppressives and sometimes antibiotics in moderate-to-severe disease; maintenance and for the treatment of selected complications. The last few years have witnessed a significant change in the treatment of Crohn's disease. Based on evidence from new clinical studies and recent meta-analyses, the role of and indications for conventional therapy have been reassessed. The 5-ASAs are nowadays less frequently used in both active disease and maintenance therapy. Instead, budesonide has been introduced in the treatment of mild-to-moderate ileal disease. Besides the modest use of 5-ASAs, steroids are prescribed for active colonic disease. Immunosuppressives, especially azathioprine, are more commonly used in moderate-to-severe disease as well as in maintenance. The preferred maintenance regimen following medically- and surgically-induced remission, in addition to relationship between medical and surgical therapies, has also changed. The recent introduction of new {"}biological{"} therapy represents a major, promising change in the therapy of resistant and penetrating disease.",
keywords = "5-ASA, Azathioprine, CD, IBD, Infliximab, Therapy",
author = "L. Lakatos and P. Lakatos",
year = "2007",
month = "6",
day = "17",
doi = "10.1556/OH.2007.28062",
language = "Hungarian",
volume = "148",
pages = "1107--1114",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "24",

}

TY - JOUR

T1 - A gyulladásos bélbetegségek gyógyszeres kezelése

T2 - Crohn-betegség

AU - Lakatos, L.

AU - Lakatos, P.

PY - 2007/6/17

Y1 - 2007/6/17

N2 - The therapy of inflammatory bowel diseases is based on 5-aminosalicylates (5-ASAs) that are the forefront of treatment of mild-to-moderate active disease and maintenance; steroids are used for the treatment of moderate-to-severe active disease; immunosuppressives and sometimes antibiotics in moderate-to-severe disease; maintenance and for the treatment of selected complications. The last few years have witnessed a significant change in the treatment of Crohn's disease. Based on evidence from new clinical studies and recent meta-analyses, the role of and indications for conventional therapy have been reassessed. The 5-ASAs are nowadays less frequently used in both active disease and maintenance therapy. Instead, budesonide has been introduced in the treatment of mild-to-moderate ileal disease. Besides the modest use of 5-ASAs, steroids are prescribed for active colonic disease. Immunosuppressives, especially azathioprine, are more commonly used in moderate-to-severe disease as well as in maintenance. The preferred maintenance regimen following medically- and surgically-induced remission, in addition to relationship between medical and surgical therapies, has also changed. The recent introduction of new "biological" therapy represents a major, promising change in the therapy of resistant and penetrating disease.

AB - The therapy of inflammatory bowel diseases is based on 5-aminosalicylates (5-ASAs) that are the forefront of treatment of mild-to-moderate active disease and maintenance; steroids are used for the treatment of moderate-to-severe active disease; immunosuppressives and sometimes antibiotics in moderate-to-severe disease; maintenance and for the treatment of selected complications. The last few years have witnessed a significant change in the treatment of Crohn's disease. Based on evidence from new clinical studies and recent meta-analyses, the role of and indications for conventional therapy have been reassessed. The 5-ASAs are nowadays less frequently used in both active disease and maintenance therapy. Instead, budesonide has been introduced in the treatment of mild-to-moderate ileal disease. Besides the modest use of 5-ASAs, steroids are prescribed for active colonic disease. Immunosuppressives, especially azathioprine, are more commonly used in moderate-to-severe disease as well as in maintenance. The preferred maintenance regimen following medically- and surgically-induced remission, in addition to relationship between medical and surgical therapies, has also changed. The recent introduction of new "biological" therapy represents a major, promising change in the therapy of resistant and penetrating disease.

KW - 5-ASA

KW - Azathioprine

KW - CD

KW - IBD

KW - Infliximab

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=34547665560&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547665560&partnerID=8YFLogxK

U2 - 10.1556/OH.2007.28062

DO - 10.1556/OH.2007.28062

M3 - Article

C2 - 17561480

AN - SCOPUS:34547665560

VL - 148

SP - 1107

EP - 1114

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 24

ER -